Serum Obestatin Levels in PCOS and its Relation with Homa-IR

Tarique Aziz, Charu Gunjal, Dr G G Kaushik

1Phd Scholar, 2Phd Scholar, 3Retired Senior Professor
Department of Biochemistry JLN Medical College Ajmer (Rajasthan)

Received: 09-06-2023 /Revised: 30-06-2023 /Accepted: 15-08-2023
DOI: https://doi.org/10.32553/ijmbs.v7i8.2740
Corresponding author: Tarique Aziz
Conflict of interest: No conflict of interest.

Abstract

Background: Is to investigate the level of Obestatin in PCOS patients and compare with controls and also see the correlations between the serum Obestatin levels and HOMA-IR.

Patients and methods: We analyzed 30 patients with PCOS and 20 normal women as controls. PCOS patients were divided into two groups based on obese group and non-obese group Serum Obestatin levels, Insulin Homeostasis Model Assessment for Insulin Resistance (HOMA-IR) determined and compared among both groups.

Results: Serum Obestatin levels were significantly lower in obese PCOS group than non-obese and control.

Introduction

Polycystic ovary syndrome (PCOS) is a common endocrine disorder in females, especially in women of reproductive age. PCOS could be diagnosed by infertility, acne, amenorrhea or oligomenorrhea, hirsutism, insulin resistance, obesity, hyperandrogenism, and polycystic ovaries by ultrasonography. Association of PCOS with infertility is well studied and is thought to be responsible for 40% of female infertility.

PCOS was first reported by Stein and Leventhal in 1935. With rising urbanisation, the disease picked up pace and it was only in 2003 that Rotterdam criteria for the diagnosis of PCOS was formulated. Primary symptoms include abnormal facial and skin growth (hirsutism) and baldness, acne, weight gain, irregular or absence of menstrual cycle and increased levels of male hormones.

PCOS is common among members of younger generation, with almost 10 million people affected globally. Its worldwide prevalence varies from 2.2% to 26% and according to latest statistics, in India one in every four young women is said to have Polycystic ovary disease (PCOD).

Obestatin, a novel 23 amino acid peptide encoded by the same gene with ghrelin and derived from the precursor protein Proghrelin. Obestatin behaves as a physiological opponent to ghrelin in inhibiting food intake, body weight gain and gastric emptying. Further studies explained that
obestatin was involved in inhibiting thirst and anxiety, improving memory, regulating sleep and increasing the secretion of pancreatic juice enzymes. Overstating could stimulate adipose cell proliferation and inhibit the secretion of IGF-1.

The present study was, therefore, undertaken to investigate the correlations between serum levels of Overstating in PCOS women and to evaluate their relationship with obesity and insulin resistance.

Methods

We analyzed 30 patients with PCOS and 20 normal women as controls. PCOS patients were divided into two groups based on obese group and non-obese group Serum Obestatin levels, Insulin Homeostasis Model Assessment for InsulinResistance (HOMA-IR) determined and compared among both groups.

Women were recruited from the department of Obstetrics and Gynecology RajkiyaMahilaChikitsalaya, Ajmer between January and August 2023

Exclusion Criteria
1. Patients with Diabetes Mellitus.
2. Patients with Hepatic and Renal dysfunction.
3. Patients with Thyroid dysfunctions.
4. Pregnant women.
5. Patients with Cardiovascular disease.

Biochemical Parameters:

Following Estimations Will Be Carried out-
Serum obestatin- ELISA method.
Insulin resistance calculated by using Homeostasis model
Fasting plasma glucose [mmol/L] X Fasting insulin [mU/L]/22.5

Results

Serum obestatin levels were significantly decreased in obese PCOS patients when compared to both control and non-obese ones.
Obestatin was negatively correlated with HOMA-IR in PCOS patients.

LEVELS OF OBESTATIN AND HOMA-IR IN OBESE PCOS AND NON OBESE PCOS AND COMPARISON WITH CONTROL

<table>
<thead>
<tr>
<th></th>
<th>Obese PCOS</th>
<th>Non Obese PCOS</th>
<th>Control</th>
</tr>
</thead>
<tbody>
<tr>
<td>Obestatin (Pg/ml)</td>
<td>2.2</td>
<td>4.7</td>
<td>6.9</td>
</tr>
<tr>
<td>HOMA-IR</td>
<td>1.7</td>
<td>0.9</td>
<td>0.8</td>
</tr>
</tbody>
</table>
Discussion

Polycystic ovaries (PCO) are the morphological ovarian phenotype in women with the polycystic ovary syndrome (PCOS). Several studies performed to attempt to determine the prevalence of PCO as detected by ultrasound alone in the general population, and have found prevalence rates in the order of 17–33%. The current study, we correlates the serum levels of Obestatin with obesity and insulin resistance in polycystic ovary, through the estimation of the serum levels of Obestatin and carotid artery intima-media thickness, brachial artery flow mediated dilatation and other metabolic and hormonal parameters in obese and non-obese women with PCOS and healthy controls.

In the present study, the obese women with PCOS have a significantly higher level of triglycerides, HOMA-IR, total testosterone, CRP, blood pressure and WHR values and lower LDH levels when compared to control and non-obese ones.

Reference


